CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company developing chimeric engulfment receptor T-cell, or CER-T, therapies targeting hematologic malignancies and solid tumors. The company entered the public markets in early 2023 through a business combination with Blue Water Acquisition Corp, a blank-check vehicle that completed its IPO in 2021 and was sponsored by Blue Water Acquisition Corp Sponsor LLC. The June 2023 Form 8-K is among CERO's earliest post-merger filings, marking its status as a newly listed oncology cell therapy company trading on Nasdaq. For a complete view of CERO's SPAC transaction history, sponsor details, and full filing timeline, sign up for data access at SpacDesk.